Sign In
Buy ATHA
$6.61
+0 (+0%)
At Close: Apr 14, 2026
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
07:00am, Wednesday, 29'th Nov 2023
Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer's disease Com
BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health a
Athira Pharma to Participate in Jefferies London Healthcare Conference
07:00am, Wednesday, 08'th Nov 2023
BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
04:30pm, Thursday, 05'th Oct 2023
New results support the neuroprotective effects of ATH-1105 in preclinical models of ALS, as indicated by consistent reduction in plasma neurofilament light chain (NfL) levels and preservation of moto
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
07:00am, Tuesday, 19'th Sep 2023
BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal healt
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
01:32pm, Friday, 08'th Sep 2023
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
11:18am, Thursday, 31'st Aug 2023
Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i
Athira Pharma to Participate in Upcoming May Investor Conferences
07:00am, Monday, 08'th May 2023
BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health a
Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock?
01:44pm, Tuesday, 28'th Mar 2023
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS HGF/MET small molecule positive modulator provides neuroprotecti
Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration
Athira Pharma to Present at Stifel 2022 Healthcare Conference
07:00am, Wednesday, 09'th Nov 2022
BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health
Data supports neuroprotective and disease modifying potential in models of Parkinson's disease and diabetic neuropathy Data supports neuroprotective and disease modifying potential in models of Parkin
Trading Ideas On The Upcoming CTAD 2022 Conference
03:27pm, Wednesday, 02'nd Nov 2022
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie
